ScreenerHero

VISTNVistin Pharma ASA

OSL · NO · Healthcare · Drug Manufacturers - Specialty & Generic · vistin.com
19.30NOK0.00%Mkt Cap: 80.00M $P/E: 12.22

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; m…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap80.00M $
Enterprise Value80.72M $
Revenue (TTM)40.38M $
Gross Profit21.68M $
Net Income (TTM)6.99M $
Revenue/Share0.9534 USD
Last Price19.30 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees74
CountryNO
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.22
P/E (Forward)—
PEG—
EV/EBITDA8.32
EV/Revenue2.00
P/S1.95
P/B2.56
EPS (TTM)1.68
EPS (Forward)—
52W Range
17.7024% of range24.40
52W High24.40 NOK
52W Low17.70 NOK
Profitability
Gross Margin51.28%
Oper. Margin16.02%
EBITDA Margin24.02%
Profit Margin16.53%
ROE22.73%
ROA17.01%
Growth
Revenue Growth-14.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF7.29M $
CapEx (TTM)1.56M $
FCF Margin10.16%
FCF Yield5.13%
Net Debt713.15K $
Net Debt/EBITDA0.07
Balance Sheet
Debt/Equity0.00
Current Ratio2.49
Quick Ratio1.52
Book Value/Sh7.415 NOK
Cash/Share0.1780 NOK
Dividends
Fwd Div Rate2.250 NOK
Trail. Div Rate0.0000 NOK
Div. Yield11.66%
5Y Avg Yield—
Payout Ratio63.29%
Ex-Div DateMay 22, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.34M
Float20.21M
Insiders58.94%
Institutions13.74%
Technical
SMA 5020.35 (-5.1%)
SMA 20020.99 (-8.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)13.64K
Avg Vol (10d)12.83K
Technical Indicators
RSI (14)34.1
MACD-0.1896
MACD Signal-0.1305
MACD Hist.-0.0591
BB Upper20.61 NOK
BB Middle20.05 NOK
BB Lower19.48 NOK
BB Width5.62%
ATR (14)0.5151 NOK
Vol Ratio (20d)1.48x